Back

QRS duration is associated with outcome in symptomatic HF patients. What about ACCF/AHA stages A and B? Data from the DAVID-Berg study

26 May 2018 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Andrea Pozzi

Hospital Valduce, Como (Italy)

22 More presentations in this session

Presentation thumbnail
Professor T. Wang (Taipei, TW)
Abstract Slides
Presentation thumbnail
Ms C. Binder (Vienna, AT)
Abstract
Presentation thumbnail
Associate Professor S. Stojkovic (Vienna, AT)
Abstract Slides
Presentation thumbnail
Mr A. Ulitin (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Doctor C. Saldarriaga (Medellin, CO)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Chronic Heart Failure – Epidemiology, Prognosis, Outcome

The Event

Event poster

Heart Failure 2018

26 May 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
A ventricular conduction delay phenotype and its outcome in heart failure with preserved ejection fraction
21 May 2023
thumbnail
Congress Session
Late-breaking science: screening for heart failure and prognostic models
18 May 2025
thumbnail
Congress Presentation
Cluster analysis to risk stratify asymptomatic subjects in stage A or B heart failure: the DAVID-Berg study
21 May 2023
thumbnail
Congress Presentation
Impact of QRS duration on drug titration and left ventricular recovery in new-onset heart failure with reduced ejection fraction
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources